Parkinson's Disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuro

Parkinson's Disease Pipeline constitutes 130+ key companies continuously working towards developing 150+ Parkinson's Disease treatment therapies, analyzes DelveInsight.

Parkinson's Disease Overview:

Parkinson's disease (PD) is a chronic, progressive neurological disorder that primarily affects movement, due to the loss of dopamine-producing neurons in the substantia nigra, a brain area responsible for motor control. It typically develops in people over 60 but can occur earlier. PD is the second most common neurodegenerative disease after Alzheimer's. Symptoms vary widely among individuals and can be difficult to predict or manage.

Key symptoms of PD include tremors, slowness of movement (bradykinesia), muscle rigidity, and balance problems, which increase the risk of falls. Non-motor symptoms such as sleep issues, depression, anxiety, and cognitive decline are also common.

The exact cause is unclear, but genetic factors (e.g., mutations in LRRK2 and SNCA) and environmental exposures (e.g., pesticides, heavy metals) may contribute. Pathologically, PD involves the accumulation of alpha-synuclein protein in Lewy bodies and a dopamine deficiency, disrupting neurotransmitter balance. Diagnosis is mainly clinical, supported by imaging techniques like DaTscan.

Currently, there is no cure for PD, but treatment focuses on managing symptoms. Levodopa is the primary medication, supplemented by dopamine agonists and MAO-B inhibitors. Advanced cases may benefit from deep brain stimulation (DBS). Physical and occupational therapies, along with lifestyle adjustments, are also important for improving quality of life.
Request for a detailed insights report on Parkinson's Disease pipeline insights @ https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Parkinson's Disease Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parkinson's Disease Therapeutics Market.

Key Takeaways from the Parkinson's Disease Pipeline Report

DelveInsight's Parkinson's Disease pipeline report depicts a robust space with 130+ active players working to develop 150+ pipeline therapies for Parkinson's Disease treatment.
In December 2024, AbbVie announced positive topline results from the Phase III TEMPO-2 trial of tavapadon, a first-in-class D1/D5 partial agonist being investigated as a once-daily treatment for Parkinson's disease. The trial met both primary and secondary endpoints, showing significant improvements in motor function. AbbVie plans to submit a New Drug Application (NDA) to the FDA in 2025.
In November 2024, Sunbird Bio revealed new data demonstrating that its diagnostic technology could accurately classify blood samples from Parkinson's disease patients with 86% accuracy by detecting aggregated alpha-synuclein proteins.
In October 2024, AbbVie announced FDA approval for VYALEV (foscarbidopa/foslevodopa), a treatment for motor fluctuations in adults with advanced Parkinson's disease. This marks the approval of the first 24-hour continuous subcutaneous infusion of a levodopa-based therapy.
Key Parkinson's Disease companies such as Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron/Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune, and others are evaluating new drugs for Parkinson's Disease to improve the treatment landscape.
Promising Parkinson's Disease pipeline therapies in various stages of development include Buntanetap, Tavapadon, Prasinezumab, Risvodetinib, GT 02287, NNI 362, and others.

Parkinson's Disease Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Parkinson's Disease Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's Disease treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Parkinson's Disease market.

Download our free sample page report on Parkinson's Disease pipeline insights @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Parkinson's Disease Emerging Drugs

Buntanetap: Annovis Bio
Tavapadon: Cerevel Therapeutics
Prasinezumab: Roche
Risvodetinib: Inhibikase Therapeutics, Inc
GT 02287: Gain Therapeutics
NNI 362: Neuronascent

Parkinson's Disease Companies

Over 130 key companies are working on developing therapies for Parkinson's disease. Among them, Annovis Bio is one of the companies with drug candidates for Parkinson's disease in the most advanced stage, Phase III.

DelveInsight's report covers around 150+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Parkinson's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Parkinson's Disease Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Parkinson's Disease Therapies and Key Companies: Parkinson's Disease Clinical Trials and advancements @ https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Parkinson's Disease Pipeline Therapeutic Assessment
• Parkinson's Disease Assessment by Product Type
• Parkinson's Disease By Stage
• Parkinson's Disease Assessment by Route of Administration
• Parkinson's Disease Assessment by Molecule Type

Download Parkinson's Disease Sample report to know in detail about the Parkinson's Disease treatment market @ Parkinson's Disease Therapeutic Assessment @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Parkinson's Disease Current Treatment Patterns
4. Parkinson's Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Parkinson's Disease Late-Stage Products (Phase-III)
7. Parkinson's Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Parkinson's Disease Discontinued Products
13. Parkinson's Disease Product Profiles
14. Parkinson's Disease Key Companies
15. Parkinson's Disease Key Products
16. Dormant and Discontinued Products
17. Parkinson's Disease Unmet Needs
18. Parkinson's Disease Future Perspectives
19. Parkinson's Disease Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Parkinson's Disease Pipeline Reports Offerings: https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.